The global hairy cell leukemia market size is anticipated to expand at a robust CAGR during the forecast period, 2021-2028. The growth of the market is attributed to rising awareness about the hairy cell leukemia coupled with rising disposable income. Moreover, increasing diagnosis rate of hairy cell leukemia is driving the market growth.
Hairy cell leukemia is a rare type of blood cancer that is caused due to abnormal growth of B- cells. The outgrown B cells or B lymphocyte when examined under a microscope looks similar to hair extending from the surface area, which gives the cancer its name. Hairy cell leukemia is characterized by the uncontrolled accumulation of lymphocytes by bone marrow.
Most of the affected individuals are males 50 years of age or older. Early diagnosis can help the patients live longer. There are advanced diagnostic tests to detect the hairy cell leukemia. In one of the diagnostic tests, the blood profile indicates the total number of lymphocytes, which indicates the disease. Physicians can easily diagnose the cancer by physical examination. Most of the patients also require bone marrow biopsy for confirmation.
Market Trends, Drivers, Restraints, and Opportunities:
- Increasing R&D activities for the development of advanced therapy is driving the growth of the market.
- Ongoing technological developments is expected to augment the hairy cell leukemia market growth.
- High cost for the treatment can act as a major restraint for the market growth.
- Efficiency of the treatment available is yet to be discover, limiting the market growth.
- State government bodies are implementing programs to increase the awareness about the cancer, which is stimulating the growth of the market.
- The presence of reimbursement programs is speculated to propel the hairy cell leukemia market.
Key Players
- Hoffmann-La Roche Ltd
- Janssen Global Services LLC
- Dr. Reddy's Laboratories
- Emcure Pharmaceuticals
- Amgen Inc.
- Hospira
- Astex Therapeutics
- Pfizer Inc
- AstraZeneca plc
- BioGenomics Limited
- Incyte Corp
- Merck & Co Inc
- Genentech
- bluebird bio
- Beam Therapeutics
- Mission Bio
- Roivant Sciences Inc.
- Humanigen
- Fate Therapeutics
- Kronos Bio
- Tasso
- PTC Therapeutics
- Quantgene
- Syros Pharmaceuticals
- Oncoternal
- GlycoMimetics
- Notable Labs
- Nuprobe
- CARsgen
- Twinstrand Biosciences Inc.
Competitive Landscape
The major players of the market are Hoffmann-La Roche Ltd, Janssen Global Services LLC, Dr.Reddy's Laboratories, Emcure Pharmaceuticals, Amgen Inc., Hospira, Astex Therapeutics, Pfizer Inc, AstraZeneca plc, BioGenomics Limited, Incyte Corp, Merck & Co Inc, Genentech, bluebird bio, Beam Therapeutics, Mission Bio, Roivant Sciences Inc., Humanigen, Fate Therapeutics, Kronos Bio, Tasso, PTC Therapeutics, Quantgene, Syros Pharmaceuticals, Oncoternal, GlycoMimetics, Notable Labs, Nuprobe, CARsgen, and Twinstrand Biosciences Inc.
Companies are focusing on innovation, partnerships, and acquisitions to expand their market share.
To Get a New Sample Request: https://growthmarketreports.com/request-sample/2042
Contact Us
- Growth Market Reports
- Phone: +1 909 414 1393
- Email: sales@growthmarketreports.com
- Web: https://growthmarketreports.com
